semaglutide clinic in roswell Eligibility: Atlanta Medical Institute Doctor's Wellness Studio (@doctorswellnessatlanta) •

Sources MHRA Drug Safety Update Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), 5 February 2026 BMJ Semaglutide and NAION, February 2026 Community Pharmacy England MHRA Drug Safety Update: Semaglutide and NAION, 5 February 2026 NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current

Ready to Explore Microdosing

The following side effects have been reported in subjects taking 3mg liraglutide for weight loss [24]: Nausea (39.3%) Diarrhea (20.9%) Constipation (19.4%) Vomiting (15.7%) Headache (up to 13.6%) Increases in mean resting heart rate (over 10% ) Less common side effects that occur in less than 10% of patients are: Dyspepsia Abdominal pain Gastroesophageal reflux disease Eructation Flatulence Dry mouth Elevated pancreatic enzymes Constipation Gastritis Abdominal discomfort Hypoglycemia Dizziness Hypotension Injection site reactions (pain, bleeding, redness, swelling, or itching) Rare but serious side effects include pancreatitis, gallbladder disease, cholestasis, and allergic reactions

Like any medication, both oral GLP-1 drugs and injections come with potential side effects